Symaptics
Symaptics: “Symaptics builds SyMAP, a pharmaceutical pricing and market access platform covering international reference pricing simulation, US Most Favored Nation policy modelling, and global revenue forecasting and optimisation. London based, founded by pharmaceutical pricing specialists.”
Do we need a SyMAP licence?
“No. You can commission a project on its own. A licence is optional if you want your team to edit and rerun models afterwards.”
View in the company profileHow long does a project take?
“Timing depends on the portfolio, markets, scenarios and available data. We agree a timescale when we scope the project.”
View in the company profileWhat access do we get to the model?
“You receive access to view and explore the project simulations in SyMAP. Editing and rerunning those models requires a subsequent platform licence.”
View in the company profileCan you use our existing data?
“Yes. We can start with your price files, forecasts and assumptions, or source and build reference data. The inputs remain visible in the analysis.”
View in the company profileCan you review analysis we already have?
“Yes. We can independently rebuild an analysis to investigate differences between models or check a result before it reaches a decision-making meeting.”
View in the company profile
More information from this source
- Pharmaceutical pricing projects and consulting
“Expert-led MFN assessments, international reference pricing analysis and launch strategy delivered in SyMAP.”